Tenecteplase versus alteplase for management of acute ischaemic stroke (NOR-TEST): a phase 3, randomised, open-label, blinded endpoint trial

The Lancet Neurology

Volumn 16, Issue 10, 2017, Pages 781-788

  Logallo, Nicola ^a,b   Novotny, Vojtech ^a,b   Assmus, Jörg ^a   Kvistad, Christopher E ^a,b   Alteheld, Lars ^c   Rønning, Ole Morten ^d,e   Thommessen, Bente ^d   Amthor, Karl Friedrich ^f   Ihle Hansen, Hege ^g   Kurz, Martin ^b,h   Tobro, Håkon ⁱ   Kaur, Kamaljit ^j   Stankiewicz, Magdalena ^k   Carlsson, Maria ^l,m   Morsund, Åse ⁿ   Idicula, Titto ^o   Aamodt, Anne Hege ^p   Lund, Christian ^p   Næss, Halvor ^a,h   Waje Andreassen, Ulrike ^a,b   Thomassen, Lars ^a,b   more..

^a HAUKELAND UNIVERSITY HOSPITAL   (Norway)

^b UNIVERSITY OF BERGEN   (Norway)

^c ULLEVÅL UNIVERSITY HOSPITAL   (Norway)

^d AKERSHUS UNIVERSITY HOSPITAL   (Norway)

^e UNIVERSITY OF OSLO   (Norway)

^f Vestre Viken Hospital Trust   (Norway)

^g VESTRE VIKEN HOSPITAL TRUST   (Norway)

^h STAVANGER UNIVERSITY HOSPITAL   (Norway)

ⁱ TELEMARK HOSPITAL   (Norway)

^j HAUGESUND HOSPITAL   (Norway)

^k Førde Central hospital   (Norway)

^l NORDLAND HOSPITAL   (Norway)

^m UNIVERSITY OF TROMSØ   (Norway)

ⁿ Møre and Romsdal Hospital Trust   (Norway)

^o TRONDHEIM UNIVERSITY HOSPITAL   (Norway)

^p OSLO UNIVERSITY HOSPITAL   (Norway)

more..

Author keywords

[No Author keywords available]

Indexed keywords

ALTEPLASE; TENECTEPLASE; FIBRINOLYTIC AGENT; TISSUE PLASMINOGEN ACTIVATOR;

ADULT; ADVERSE EVENT; AGED; ANGIONEUROTIC EDEMA; AROUSAL; ARTICLE; BLOOD CLOT LYSIS; BRAIN HEMORRHAGE; BRAIN ISCHEMIA; CLINICAL ASSESSMENT; CONTROLLED STUDY; DIFFUSION WEIGHTED IMAGING; DRUG EFFICACY; DRUG SAFETY; EPISTAXIS; FEMALE; FLUID ATTENUATED INVERSION RECOVERY IMAGING; GASTROINTESTINAL HEMORRHAGE; HOSPITAL ADMISSION; HUMAN; INTENTION TO TREAT ANALYSIS; MAJOR CLINICAL STUDY; MALE; MANAGED CARE; MULTICENTER STUDY; NATIONAL INSTITUTES OF HEALTH STROKE SCALE; NUCLEAR MAGNETIC RESONANCE IMAGING; OUTCOME ASSESSMENT; PHASE 3 CLINICAL TRIAL; PRACTICE GUIDELINE; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; RANKIN SCALE; SINGLE BLIND PROCEDURE; STROKE UNIT; SYMPTOM; THORAX PAIN; THROMBECTOMY; TRANSIENT ISCHEMIC ATTACK; TREATMENT DURATION; VERY ELDERLY; CLINICAL TRIAL; COMPARATIVE STUDY; DOUBLE BLIND PROCEDURE; MIDDLE AGED; NORWAY; STROKE;

AGED; AGED, 80 AND OVER; BRAIN ISCHEMIA; DOUBLE-BLIND METHOD; FEMALE; FIBRINOLYTIC AGENTS; HUMANS; MALE; MIDDLE AGED; NORWAY; OUTCOME ASSESSMENT (HEALTH CARE); STROKE; TISSUE PLASMINOGEN ACTIVATOR;

EID: 85026678194     PISSN: 14744422     EISSN: 14744465     Source Type: Journal    
DOI: 10.1016/S1474-4422(17)30253-3     Document Type: Article

References (25)

1. Lees, KR, Bluhmki, E, von Kummer, R, et al. Time to treatment with intravenous alteplase and outcome in stroke: an updated pooled analysis of ECASS, ATLANTIS, NINDS, and EPITHET trials. Lancet 375 (2010), 1695–1703.
2. Bhatia, R, Hill, MD, Shobha, N, et al. Low rates of acute recanalization with intravenous recombinant tissue plasminogen activator in ischemic stroke: real-world experience and a call for action. Stroke 41 (2010), 2254–2258.
3. Whiteley, WN, Emberson, J, Lees, KR, et al. Risk of intracerebral haemorrhage with alteplase after acute ischaemic stroke: a secondary analysis of an individual patient data meta-analysis. Lancet Neurol 15 (2016), 925–933.
4. Logallo, N, Kvistad, CE, Thomassen, L, Therapeutic potential of tenecteplase in the management of acute ischemic stroke. CNS Drugs 29 (2015), 811–818.
5. Benedict, CR, Refino, CJ, Keyt, BA, et al. New variant of human tissue plasminogen activator (TPA) with enhanced efficacy and lower incidence of bleeding compared with recombinant human TPA. Circulation 92 (1995), 3032–3040.
6. Van De Werf, F, Adgey, J, Ardissino, D, et al., for the Assessment of the Safety and Efficacy of a New Thrombolytic (ASSENT-2) Investigators. Single-bolus tenecteplase compared with front-loaded alteplase in acute myocardial infarction: the ASSENT-2 double-blind randomised trial. Lancet 354 (1999), 716–722.
7. Parsons, M, Spratt, N, Bivard, A, et al. A randomized trial of tenecteplase versus alteplase for acute ischemic stroke. N Engl J Med 366 (2012), 1099–1107.
8. Huang, X, Cheripelli, BK, Lloyd, SM, et al. Alteplase versus tenecteplase for thrombolysis after ischaemic stroke (ATTEST): a phase 2, randomised, open-label, blinded endpoint study. Lancet Neurol 14 (2015), 368–376.
9. Indredavik, B, Salvesen, R, Naess, H, Nasjonal retningslinje for behandling og rehabilitering ved hjerneslag, 2010, Helsedirektoratet, Oslo, 1–196.
10. European Stroke Organisation Executive Commitee, ESO Writing Committee. Guidelines for management of ischaemic stroke and transient ischaemic attack 2008. Cerebrovasc Dis 25 (2008), 457–507.
11. Thomalla, G, Cheng, B, Ebinger, M, et al. DWI-FLAIR mismatch for the identification of patients with acute ischaemic stroke within 4.5 h of symptom onset (PRE-FLAIR): a multicentre observational study. Lancet Neurol 10 (2011), 978–986.
12. Logallo, N, Kvistad, CE, Nacu, A, et al. The Norwegian tenecteplase stroke trial (NOR-TEST): randomised controlled trial of tenecteplase vs. alteplase in acute ischaemic stroke. BMC Neurol, 14, 2014, 106.
13. Hacke, W, Kaste, M, Fieschi, C, et al. Intravenous thrombolysis with recombinant tissue plasminogen activator for acute hemispheric stroke. The European Cooperative Acute Stroke Study (ECASS). JAMA 274 (1995), 1017–1025.
14. Hacke, W, Kaste, M, Bluhmki, E, et al. Thrombolysis with alteplase 3 to 4.5 hours after acute ischemic stroke. N Engl J Med 359 (2008), 1317–1329.
15. Hacke, W, Donnan, G, Fieschi, C, et al. Association of outcome with early stroke treatment: pooled analysis of ATLANTIS, ECASS, and NINDS rt-PA stroke trials. Lancet 363 (2004), 768–774.
16. Wahlgren, N, Ahmed, N, Davalos, A, et al. Thrombolysis with alteplase for acute ischaemic stroke in the Safe Implementation of Thrombolysis in Stroke-Monitoring Study (SITS-MOST): an observational study. Lancet 369 (2007), 275–282.
17. Ahmed, N, Wahlgren, N, Grond, M, et al. Implementation and outcome of thrombolysis with alteplase 3-4.5 h after an acute stroke: an updated analysis from SITS-ISTR. Lancet Neurol 9 (2010), 866–874.
18. Bath, PM, Lees, KR, Schellinger, PD, et al. Statistical analysis of the primary outcome in acute stroke trials. Stroke 43 (2012), 1171–1178.
19. Nacu, A, Kvistad, CE, Naess, H, et al. NOR-SASS (Norwegian Sonothrombolysis in Acute Stroke Study): randomized controlled contrast-enhanced sonothrombolysis in an unselected acute ischemic stroke population. Stroke 48 (2017), 335–341.
20. Haley, EC Jr, Thompson, JL, Grotta, JC, et al. Phase IIB/III trial of tenecteplase in acute ischemic stroke: results of a prematurely terminated randomized clinical trial. Stroke 41 (2010), 707–711.
21. Haley, EC Jr, Lyden, PD, Johnston, KC, Hemmen, TM, TNK in Stroke Investigators. A pilot dose-escalation safety study of tenecteplase in acute ischemic stroke. Stroke 36 (2005), 607–612.
22. Molina, CA, Ribo, M, Rubiera, M, et al. TNK induces faster MCA recanalization and leads to better short- and long-term clinical outcome than native tPA. The TNK-TPA reperfusion stroke study. Stroke, 39, 2008, 563 (abstr).
23. Tanswell, P, Modi, N, Combs, D, Danays, T, Pharmacokinetics and pharmacodynamics of tenecteplase in fibrinolytic therapy of acute myocardial infarction. Clin Pharmacokinet 41 (2002), 1229–1245.
24. Cannon, CP, Gibson, CM, McCabe, CH, et al. TNK-tissue plasminogen activator compared with front-loaded alteplase in acute myocardial infarction: results of the TIMI 10B trial. Thrombolysis in Myocardial Infarction (TIMI) 10B Investigators. Circulation 98 (1998), 2805–2814.
25. Van de Werf, F, Cannon, CP, Luyten, A, et al. Safety assessment of single-bolus administration of TNK tissue-plasminogen activator in acute myocardial infarction: the ASSENT-1 trial. The ASSENT-1 Investigators. Am Heart J 137 (1999), 786–791.